Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach
Highlights
– Co-infusion of autologous anti‑CD19 and anti‑BCMA CAR‑T cells induced LLDAS and DORIS remission in 12/15 (80%) treatment‑refractory SLE patients by week 12 with a median follow‑up of 712 days.
– No dose‑limiting toxicities (DLTs) or treatment‑related deaths; grade 1 CRS was common (86.7%); grade ≥3 cytopenias (neutropenia 100%, thrombocytopenia 40%, anemia 13.3%) were reversible with supportive care.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.